Neovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Anti-VEGF treatment has undoubtedly revolutionized how ophthalmologists manage patients with AMD. But have we leveled out? And, more importantly, how do we break through the plateau?